

**7-5/2024/EU/WC-0583**  
Government of India  
Directorate General of Health Services  
Central Drugs Standard Control Organisation  
(International Cell)

FDA Bhawan, Kotla Road,  
New Delhi-110002

**Dated:**

10 JUN 2024

To,

**M/s. IPCA Laboratories Limited,  
Plot No. -16 -22, Industrial Area No.01,  
A.B. Road, District – Dewas, Madhya Pradesh, India**

**SUB:-** Written Confirmation of M M/s. IPCA Laboratories Limited, Plot No.-16 -22, Industrial Area No.01, A.B. Road, District – Dewas, Madhya Pradesh, India, as per requirement of EU for import of active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India-Reg.

**Sir,**

Please refer to your online application no. WC/FR/2024/8214 dated 27.03.2024 submitted to DDC(I), CDSCO, Sub-Zone, Indore and the recommendation received from DDC(I), CDSCO, Sub-Zone, Indore on the above noted subject.

Written Confirmation as required for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India is herewith granted subject to the following conditions:-

1. The Active Pharmaceutical Ingredients shall confirm to Good Manufacturing Practices mentioned in the EU directives or other equivalent (GMP of WHO/ICH Q7).
2. The manufacturer is subject to regular, strict and transparent controls and to the effective enforcement of Good Manufacturing Practice, including repeated and unannounced inspections, so as to ensure a protection of public health equivalent to that in the EU.
3. The manufacturer is required to follow the Guidance document for Issue of Written Confirmation as issued by CDSCO.
4. Written Confirmation shall be produced by the Authorized Exporter as and when required by the Drug Regulatory Authority.

5. The Written Confirmation will be withdrawn in the events of non compliance of Standards.
6. This Written Confirmation, unless it is sooner suspended or cancelled, shall be valid for a period of three years.
7. In the event of any Non Compliance observed during inspections conducted by Local or International Drug Authorities, the same shall be forwarded to this office within 7 days of receipt of report.
8. In the event of any drug found not of standard quality, the same shall be reported to this office within 7 days of receipt of report.
9. The manufacturer is required to comply to the provisions of GSR 20(E) dated 18.01.2022.

Please note that Written Confirmation issued is liable to be suspended / cancelled, if any of the conditions stipulated above are not complied with or in case of violation of the provisions of the Drugs & Cosmetics Act, 1940 and the Rules thereunder as the case may be.

Please acknowledge the receipt.

Annexure No.	No. of Products	Date of Issue	Valid Upto
-----	05	10 JUN 2024	Three years from the date of issue

Yours faithfully,

  
(Dr. Rajeev Singh Raghuvanshi)  
Drugs Controller General (India)



Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

1. Name and address of site: **M/s. IPCA Laboratories Limited,**  
**Plot No. -16 -22, Industrial Area No.01,**  
**A.B. Road, District – Dewas, Madhya Pradesh, India**

2. Manufacturer's licence number: **25/151/2022**

Regarding the manufacturing plant under (1) of the following Active substance(s) exported to the EU for medicinal products for human use

**List of API(s):**

S. No.	Active substance(s)	Activity(ies)
1.	Etodolac IP/BP/Ph.Eur/USP	Manufacturing & Packing
2.	Metoclopramide Hydrochloride IP/BP/Ph.Eur/USP	Manufacturing & Packing
3.	Valsartan IP/BP/Ph.Eur/USP	Manufacturing & Packing
4.	Telmisartan IP/BP/Ph.Eur/USP	Manufacturing & Packing
5.	Chlorthalidone IP/BP/Ph.Eur/USP	Manufacturing & Packing

The issuing Regulatory Authority hereby confirms that:

The standards of good manufacturing practice applicable to this manufacturing plant are at least equivalent to those laid down in the EU(= GMP of WHO/ICH Q7);

The manufacturing plant is subject to regular, strict and transparent controls and to the effective enforcement of good manufacturing practice, including repeated and unannounced inspections, so as to ensure a protection of public health at least equivalent to that in the EU; and

In the event of findings relating to non-compliance, information on such findings is supplied by the exporting third country without delay to the EU.

**Date of Inspection of the plant: 13.06.2023 to 14.06.2023**

**The Written Confirmation remains valid until: Three Years from the Date of Issue**

The authenticity of this written confirmation may be verified with the issuing regulatory authority.

This written confirmation is without prejudice to the responsibilities of the manufacturer to ensure the quality of the medicinal product in accordance with Directive 2001/83/EC.

**Address of the issuing regulatory authority: Central Drugs Standard Control Organisation**  
FDA Bhawan, Kotla Road,  
New Delhi- 110 002, India

**Name and function of responsible person:** Dr. Rajeev Singh Raghuvanshi,  
Drugs Controller General (India)

**E-mail:** dci@nic.in,  
**Telephone no.:** +91-11-23236965  
**Fax no.:** +91-11-23236973

  
Signature

10 JUN 2024



Stamp of the authority and date